SEC Form 4 · accession 0001209191-18-054248
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Oct 2, 2018
Accepted (ET)
Oct 4, 2018 · 4:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 2, 2018 | M | 5,000 | $5.5004 | A | 29,905 | D | |
| Common StockF2 | Oct 2, 2018 | S | 4,552 | $139.2551 | D | 25,353 | D | |
| Common StockF3 | Oct 2, 2018 | S | 448 | $139.9532 | D | 24,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $5.5004 | Oct 2, 2018 | M | 5,000 | D | — | Jan 16, 2023 | Common Stock | 5,000 | 31,951 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
- F2The range in prices for the transaction reported on this line was $138.80 to $139.76. The average weighted price was $139.2551. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range in prices for the transaction reported on this line was $139.81 to $140.29. The average weighted price was $139.9532. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.